Abstract
Nitric oxide (NO) releasing drugs have helped patients suffering from angina pectoris for more than a century. In the 1970s NO-sensitive guanylyl cyclase was identified as the target of NO. Since then, three different isoforms of the enzyme have been identified. All NO-releasing drugs act by binding of NO to the prosthetic heme group common to all three isoforms. They thus act all as isoform-unspecific substances. This review addresses recently developed drugs that activate NO-sensitive guanylyl cyclase independent of NOrelease. They have great potential in the treatment of angina pectoris, hypertension and erectile dysfunction. The molecular target has been validated by the successful clinical use of NO-releasing drugs for more than a century. At the same time the mode of action of these drugs is entirely new. The development of highly isoform-specific derivatives with distinct pharmacological profiles is now an open possibility with great potential.
Keywords: nitric oxide, guanylyl cyclase, glyceryl trinitrste, bay41-2272, bay41-8543, bay58-2667
Current Medicinal Chemistry
Title: Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release
Volume: 10 Issue: 4
Author(s): Sonke Behrends
Affiliation:
Keywords: nitric oxide, guanylyl cyclase, glyceryl trinitrste, bay41-2272, bay41-8543, bay58-2667
Abstract: Nitric oxide (NO) releasing drugs have helped patients suffering from angina pectoris for more than a century. In the 1970s NO-sensitive guanylyl cyclase was identified as the target of NO. Since then, three different isoforms of the enzyme have been identified. All NO-releasing drugs act by binding of NO to the prosthetic heme group common to all three isoforms. They thus act all as isoform-unspecific substances. This review addresses recently developed drugs that activate NO-sensitive guanylyl cyclase independent of NOrelease. They have great potential in the treatment of angina pectoris, hypertension and erectile dysfunction. The molecular target has been validated by the successful clinical use of NO-releasing drugs for more than a century. At the same time the mode of action of these drugs is entirely new. The development of highly isoform-specific derivatives with distinct pharmacological profiles is now an open possibility with great potential.
Export Options
About this article
Cite this article as:
Behrends Sonke, Drugs that Activate Specific Nitric Oxide Sensitive Guanylyl Cyclase Isoforms Independent of Nitric Oxide Release, Current Medicinal Chemistry 2003; 10 (4) . https://dx.doi.org/10.2174/0929867033368286
DOI https://dx.doi.org/10.2174/0929867033368286 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Magnesium and Anaesthesia
Current Drug Targets Consequences of Type 1 and 2 Diabetes Mellitus on the Cardiovascular Regulation During Exercise: A Brief Review
Current Diabetes Reviews Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Endothelin-1 Impairs Retrograde Axonal Transport and Leads to Axonal Injury in Rat Optic Nerve
Current Neurovascular Research The Frequency and Risk Factors of Diabetic Foot Ulcer Recurrence Among Jordanian Patients with Diabetes
Current Diabetes Reviews Hepatocellular Carcinoma in Alcoholic Liver Disease: Current Management and Recent Advances
Reviews on Recent Clinical Trials Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Potential Applications of RNA Interference-Based Therapeutics in the Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Rapid Screening of Antioxidant Active Constituents from Puerariae Lobatae Radix Based on the Investigation of Quantitative Patteren-Activity Relationship
Current Analytical Chemistry Advances in Sickle Cell Disease Treatments
Current Medicinal Chemistry Renal Biopsy Research with Implications for Therapy of Glomerulonephritis
Current Drug Therapy Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism